Jazz Pharmaceuticals Completes $820M Acquisition of Actio Biosciences

Overview of Event

On September 15, 2026, Jazz Pharmaceuticals plc announced the completion of its acquisition of privately held Actio Biosciences, Inc. for an upfront purchase price of $820 million.

Strategic Rationale & Asset Details

• Lead Asset (ABS-1230): The transaction brings ABS-1230 into Jazz's rare disease and neuroscience pipeline. ABS-1230 is an orally available, selective small-molecule inhibitor of KCNT1 designed to treat KCNT1-related epilepsy.
• Clinical & Preclinical Data: In preclinical studies, ABS-1230 demonstrated inhibition across all evaluable pathogenic mutations. Early clinical proof-of-concept testing showed meaningful seizure reductions in pediatric patients.
• Designations: ABS-1230 has received Fast Track, Rare Pediatric Disease, and Orphan Drug designations from the U.S. FDA, and is accepted into the FDA's Rare Disease Evidence Principles process.

Transaction Structure

• The acquisition was structured as a merger of Knight Acquisition Corp., an indirect wholly-owned subsidiary of Jazz, with and into Actio, leaving Actio as the surviving entity.
• Actio spun out its non-ABS-1230 programs into a newly formed independent entity funded by existing investors, with Jazz retaining a minority stake.